MBF-015 / Medibiofarma - LARVOL DELTA

Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of MBF-015 in Huntington's Disease Patients (clinicaltrials.gov) - P2 | N=10 | Completed | Sponsor: Medibiofarma S.L. | Recruiting ➔ Completed | Trial completion date: Apr 2025 ➔ Dec 2024

Trial completion • Trial completion date • Genetic Disorders • Huntington's Disease • Movement Disorders

Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of MBF-015 in Huntington's Disease Patients (clinicaltrials.gov) - P2 | N=10 | Recruiting | Sponsor: Medibiofarma S.L.

New P2 trial • Genetic Disorders • Huntington's Disease • Movement Disorders

Study to Assess the Safety and Tolerability of MBF-015 in Healthy Young Volunteers (clinicaltrials.gov) - P1 | N=72 | Completed | Sponsor: Medibiofarma S.L.

New P1 trial